These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11367331)

  • 1. Dupont data supports earlier findings.
    Slovick J
    Posit Living; 1999 Nov; 8(10):45. PubMed ID: 11367331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New study shows efavirenz effective with d4T and 3TC.
    AIDS Alert; 1999 May; 14(5):60. PubMed ID: 11366404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Don't mix Sustiva with Fortovase.
    Posit Aware; 1998; 9(5):17. PubMed ID: 11365885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustiva (efavirenz) is approved.
    Vazquez E
    Posit Aware; 1998; 9(6):17. PubMed ID: 11366471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of the naive patient.
    Bartlett JG
    Hopkins HIV Rep; 1999 Mar; 11(2):1, 10-1. PubMed ID: 11366244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-HIV therapy trials: new studies and follow-up of existing trials.
    Bartnof HS
    BETA; 1999; 12(4):58-60. PubMed ID: 11367257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination.
    James JS
    AIDS Treat News; 1998 Jul; (No 299):1-3. PubMed ID: 11365599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conference updates show promising drug data.
    AIDS Alert; 1997 Nov; 12(11):125-6. PubMed ID: 11364769
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination study for children.
    Vazquez E
    Posit Aware; 1998; 9(1):15. PubMed ID: 11364991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new HAART on the horizon says the proof is in the potency.
    AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
    Staszewski S; Morales-Ramirez J; Tashima KT; Rachlis A; Skiest D; Stanford J; Stryker R; Johnson P; Labriola DF; Farina D; Manion DJ; Ruiz NM
    N Engl J Med; 1999 Dec; 341(25):1865-73. PubMed ID: 10601505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [FDA approval of the first HIV anti-retroviral from DuPont-Pharma: SUSTIVA (efavirenz). SUSTIVA should be associated with other anti-retrovirals and could be considered a new alternative first line treatment].
    Allerg Immunol (Paris); 1998 Oct; 30(8):268-70. PubMed ID: 9846197
    [No Abstract]   [Full Text] [Related]  

  • 13. [HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
    Allerg Immunol (Paris); 1998 Apr; 30(4):123-4. PubMed ID: 9631694
    [No Abstract]   [Full Text] [Related]  

  • 14. Now approved: Sustiva in combination offers patients a new first-line therapy.
    Fac Notes (New Orleans La); 1998; 10(6):10. PubMed ID: 11366140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiretroviral update from the Interscience Conference on Antimicrobial Agents and Chemotherapy.
    Newsline People AIDS Coalit N Y; 1998 Dec; ():16-8. PubMed ID: 11367083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sustiva granted full FDA approval.
    AIDS Read; 2000 Mar; 10(3):147. PubMed ID: 10798886
    [No Abstract]   [Full Text] [Related]  

  • 17. Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz.
    AIDS Treat News; 1997 Dec; (No 284):4. PubMed ID: 11364914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DMP 266 now available.
    Gilden D
    GMHC Treat Issues; 1997 Sep; 11(9):5-6. PubMed ID: 11364751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dupont pharmaceuticals study 006 for Sustiva.
    Bartlett JG
    Hopkins HIV Rep; 1998 Sep; 10(5):1. PubMed ID: 11365772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preparing for the future.
    Cox S
    Posit Aware; 1997; 8(2):10-1. PubMed ID: 11364448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.